Like many degenerative brain diseases, including Parkinson's and Alzheimer's, proteins targeted in the disease process begin misfolding and clumping in or around brain cells, which are called neurons.
Amgen's decision reverberated beyond the 48 patients in the trials because the drug, called glial cell line-derived neurotrophic factor, or GDNF, had the potential to stall or even reverse the progression of the disease rather than just reduce the symptoms, as the currently available Parkinson's drugs do.
